このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Marksans Pharma バランスシートの健全性
財務の健全性 基準チェック /66
Marksans Pharmaの総株主資本は₹20.9B 、総負債は₹290.9Mで、負債比率は1.4%となります。総資産と総負債はそれぞれ₹26.8Bと₹6.0Bです。 Marksans Pharmaの EBIT は₹3.8Bで、利息カバレッジ比率34.3です。現金および短期投資は₹7.0Bです。
主要情報
1.4%
負債資本比率
₹290.91m
負債
| インタレスト・カバレッジ・レシオ | 34.3x |
| 現金 | ₹7.01b |
| エクイティ | ₹20.86b |
| 負債合計 | ₹5.95b |
| 総資産 | ₹26.81b |
財務の健全性に関する最新情報
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Recent updates
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08財務状況分析
短期負債: MARKSANSの 短期資産 ( ₹18.6B ) が 短期負債 ( ₹3.9B ) を超えています。
長期負債: MARKSANSの短期資産 ( ₹18.6B ) が 長期負債 ( ₹2.1B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: MARKSANS総負債よりも多くの現金を保有しています。
負債の削減: MARKSANSの負債対資本比率は、過去 5 年間で19.9%から1.4%に減少しました。
債務返済能力: MARKSANSの負債は 営業キャッシュフロー によって 十分にカバー されています ( 792% )。
インタレストカバレッジ: MARKSANSの負債に対する 利息支払い は EBIT ( 34.3 x coverage) によって 十分にカバーされています。